FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2267949278> ?p ?o ?g. }

• W2267949278 endingPage "e0144488" @default.
• W2267949278 startingPage "e0144488" @default.
• W2267949278 abstract "Prognosis remains extremely poor for malignant glioma. Targeted therapeutic approaches, including single agent anti-angiogenic and proteasome inhibition strategies, have not resulted in sustained anti-glioma clinical efficacy. We tested the anti-glioma efficacy of the anti-angiogenic receptor tyrosine kinase inhibitor cediranib and the novel proteasome inhibitor SC68896, in combination and as single agents. To assess anti-angiogenic effects and evaluate efficacy we employed 4C8 intracranial mouse glioma and a dual-bolus perfusion MRI approach to measure Ktrans, relative cerebral blood flow and volume (rCBF, rCBV), and relative mean transit time (rMTT) in combination with anatomical MRI measurements of tumor growth. While single agent cediranib or SC68896 treatment did not alter tumor growth or survival, combined cediranib/SC68896 significantly delayed tumor growth and increased median survival by 2-fold, compared to untreated. This was accompanied by substantially increased tumor necrosis in the cediranib/SC68896 group (p<0.01), not observed with single agent treatments. Mean vessel density was significantly lower, and mean vessel lumen area was significantly higher, for the combined cediranib/SC68896 group versus untreated. Consistent with our previous findings, cediranib alone did not significantly alter mean tumor rCBF, rCBV, rMTT, or Ktrans. In contrast, SC68896 reduced rCBF in comparison to untreated, but without concomitant reductions in rCBV, rMTT, or Ktrans. Importantly, combined cediranib/SC68896 substantially reduced rCBF, rCBV. rMTT, and Ktrans. A novel analysis of Ktrans/rCBV suggests that changes in Ktrans with time and/or treatment are related to altered total vascular surface area. The data suggest that combined cediranib/SC68896 induced potent anti-angiogenic effects, resulting in increased vascular efficiency and reduced extravasation, consistent with a process of vascular normalization. The study represents the first demonstration that the combination of cediranib with a proteasome inhibitor substantially increases the anti-angiogenic efficacy produced from either agent alone, and synergistically slows glioma tumor growth and extends survival, suggesting a promising treatment which warrants further investigation." @default.
• W2267949278 created "2016-06-24" @default.
• W2267949278 creator A5006127652 @default.
• W2267949278 creator A5013595883 @default.
• W2267949278 creator A5014191604 @default.
• W2267949278 creator A5020784702 @default.
• W2267949278 creator A5025712547 @default.
• W2267949278 creator A5043158762 @default.
• W2267949278 creator A5044026062 @default.
• W2267949278 creator A5079843220 @default.
• W2267949278 creator A5090074550 @default.
• W2267949278 date "2015-12-08" @default.
• W2267949278 modified "2023-10-18" @default.
• W2267949278 title "Synergistic Antivascular and Antitumor Efficacy with Combined Cediranib and SC6889 in Intracranial Mouse Glioma" @default.
• W2267949278 cites W1654790906 @default.
• W2267949278 cites W1937468351 @default.
• W2267949278 cites W1965827991 @default.
• W2267949278 cites W1970001436 @default.
• W2267949278 cites W1972076184 @default.
• W2267949278 cites W1974749881 @default.
• W2267949278 cites W1982246823 @default.
• W2267949278 cites W1988692970 @default.
• W2267949278 cites W1989976732 @default.
• W2267949278 cites W1995786747 @default.
• W2267949278 cites W1999614991 @default.
• W2267949278 cites W2001742494 @default.
• W2267949278 cites W2006571965 @default.
• W2267949278 cites W2008648506 @default.
• W2267949278 cites W2010033523 @default.
• W2267949278 cites W2011810742 @default.
• W2267949278 cites W2017322644 @default.
• W2267949278 cites W2027250628 @default.
• W2267949278 cites W2032900860 @default.
• W2267949278 cites W2036941876 @default.
• W2267949278 cites W2040095107 @default.
• W2267949278 cites W2041532314 @default.
• W2267949278 cites W2041581075 @default.
• W2267949278 cites W2042098439 @default.
• W2267949278 cites W2047232697 @default.
• W2267949278 cites W2054245110 @default.
• W2267949278 cites W2056915091 @default.
• W2267949278 cites W2061255952 @default.
• W2267949278 cites W2061478772 @default.
• W2267949278 cites W2065777825 @default.
• W2267949278 cites W2067216473 @default.
• W2267949278 cites W2070412580 @default.
• W2267949278 cites W2071898325 @default.
• W2267949278 cites W2073277210 @default.
• W2267949278 cites W2074145540 @default.
• W2267949278 cites W2077247713 @default.
• W2267949278 cites W2079111811 @default.
• W2267949278 cites W2081753042 @default.
• W2267949278 cites W2090171472 @default.
• W2267949278 cites W2090625794 @default.
• W2267949278 cites W2091320739 @default.
• W2267949278 cites W2096287682 @default.
• W2267949278 cites W2097373408 @default.
• W2267949278 cites W2100823015 @default.
• W2267949278 cites W2108430781 @default.
• W2267949278 cites W2114052327 @default.
• W2267949278 cites W2115852392 @default.
• W2267949278 cites W2115862526 @default.
• W2267949278 cites W2121398618 @default.
• W2267949278 cites W2122937570 @default.
• W2267949278 cites W2128687105 @default.
• W2267949278 cites W2129515878 @default.
• W2267949278 cites W2133554539 @default.
• W2267949278 cites W2134431790 @default.
• W2267949278 cites W2134791874 @default.
• W2267949278 cites W2135201636 @default.
• W2267949278 cites W2137511738 @default.
• W2267949278 cites W2144428144 @default.
• W2267949278 cites W2149035426 @default.
• W2267949278 cites W2151859384 @default.
• W2267949278 cites W2158794607 @default.
• W2267949278 cites W2159294806 @default.
• W2267949278 cites W2165611334 @default.
• W2267949278 cites W2166222647 @default.
• W2267949278 cites W4253190278 @default.
• W2267949278 doi "https://doi.org/10.1371/journal.pone.0144488" @default.
• W2267949278 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4672903" @default.
• W2267949278 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26645398" @default.
• W2267949278 hasPublicationYear "2015" @default.
• W2267949278 type Work @default.
• W2267949278 sameAs 2267949278 @default.
• W2267949278 citedByCount "6" @default.
• W2267949278 countsByYear W22679492782017 @default.
• W2267949278 countsByYear W22679492782018 @default.
• W2267949278 countsByYear W22679492782020 @default.
• W2267949278 crossrefType "journal-article" @default.
• W2267949278 hasAuthorship W2267949278A5006127652 @default.
• W2267949278 hasAuthorship W2267949278A5013595883 @default.
• W2267949278 hasAuthorship W2267949278A5014191604 @default.
• W2267949278 hasAuthorship W2267949278A5020784702 @default.
• W2267949278 hasAuthorship W2267949278A5025712547 @default.
• W2267949278 hasAuthorship W2267949278A5043158762 @default.
• W2267949278 hasAuthorship W2267949278A5044026062 @default.
• W2267949278 hasAuthorship W2267949278A5079843220 @default.

• next